Abstract
Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Current Vascular Pharmacology
Title: Visfatin/PBEF and Atherosclerosis-Related Diseases
Volume: 8 Issue: 1
Author(s): Theodosios D. Filippatos, Harpal S. Randeva, Christos S. Derdemezis, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Abstract: Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Export Options
About this article
Cite this article as:
Filippatos D. Theodosios, Randeva S. Harpal, Derdemezis S. Christos, Elisaf S. Moses and Mikhailidis P. Dimitri, Visfatin/PBEF and Atherosclerosis-Related Diseases, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226679
DOI https://dx.doi.org/10.2174/157016110790226679 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Measuring Glycaemic Variation
Current Diabetes Reviews Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of Non-antihypertensive Drugs on Endothelial Function in Hypertensive Subjects Evaluated by Flow-mediated Vasodilation
Current Vascular Pharmacology Results of Controlled Clinical Trials Comparing “Guideline Exposed” and “Guideline Naive” Physicians in the Treatment of Depression, Hypertension,and Diabetes: What can be Learned?
Current Psychiatry Reviews Molecular and Pathophysiological Mechanisms of Diabetic Retinopathy in Relation to Adhesion Molecules
Current Diabetes Reviews Model Checking a Synchronous Diabetes-Cancer Logical Network
Current Bioinformatics Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Pharmacological Effects of Secondary Bile Acid Microparticles in Diabetic Murine Model
Current Diabetes Reviews Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity
Current Analytical Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism